Company Filing History:
Years Active: 2015-2016
Title: Mi-Hee Park: Innovator in Monoclonal Antibody Research
Introduction
Mi-Hee Park is a prominent inventor based in Daejeon, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents to her name, her work is paving the way for advancements in cancer treatment.
Latest Patents
One of Mi-Hee Park's latest patents is focused on a human monoclonal antibody that neutralizes vascular endothelial growth factor receptor. This invention relates specifically to human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptor. It has shown effectiveness not only in humans but also in mice and rats, making it a valuable asset in anticancer studies.
Career Highlights
Mi-Hee Park is currently associated with Pharmabcine Inc., where she continues her research and development efforts. Her innovative work in the field of monoclonal antibodies has garnered attention and respect within the scientific community.
Collaborations
Throughout her career, Mi-Hee Park has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Mi-Hee Park is a trailblazer in the field of monoclonal antibody research, with her inventions holding promise for future cancer therapies. Her contributions are significant and continue to impact the scientific community positively.